Media Contacts:

Katrine Sperling
Tel: (+45) 4442 6718
krsp@novonordisk.com

In North America:
Sarah Spielvogel
Tel: (+1) 609 786 4278
sspv@novonordisk.com

Novo Nordisk Receives U.S. FDA approval for NovoLog® FlexTouch® and Levemir® FlexTouch®

Plainsboro, N.J. (November 1, 2013) /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) has approved the prefilled insulin pens NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch® and Levemir® (insulin detemir [rDNA origin] injection) FlexTouch®. FlexTouch® is a new prefilled insulin delivery system from Novo Nordisk.

When a dose is dialed with traditional prefilled pens, the push button extends, and at larger doses this can present challenges for the patient. The unique dosing mechanism of FlexTouch® ensures the push-button does not extend at any dose and allows insulin to be administered by pressing the low dose force button.

“Novo Nordisk is committed to continuously introducing new solutions that can improve the lives of people with diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “This approval marks another advancement in insulin delivery and an important milestone for Novo Nordisk.”

Novo Nordisk plans to make NovoLog® FlexTouch® and Levemir® FlexTouch® available in the U.S. within the next year. FlexTouch® was approved by the European Commission in July 2011 and has launched in several countries, including the United Kingdom, Canada, Denmark and Japan.

For more information on Novo Nordisk products, please visit www.novonordisk-us.com.

About NovoLog® FlexTouch®
NovoLog® FlexTouch® is a prefilled insulin pen containing 300 units of insulin aspart. The pen doses in 1 unit increments, from 1 to 80 units and is compatible with both NovoFine® and the latest NovoTwist® needles.

NovoTwist® comes in 5 mm (32G Tip) and 8 mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.

Indications and Usage
What is NovoLog® (insulin aspart [rDNA origin] injection)?

Important Safety Information
Who should not use NovoLog®?

What should I tell my health care provider before taking NovoLog®?

How should I take NovoLog®?

What should I consider while using NovoLog®?

What are the possible side effects of NovoLog® (insulin aspart [rDNA origin] injection)?

Please visit novolog.com for Prescribing Information.

About Levemir® FlexTouch®
Levemir® FlexTouch® is a prefilled insulin pen containing 300 units of insulin detemir. The pen doses in 1 unit increments, from 1 to 80 units and is compatible with both NovoFine® and the latest NovoTwist® needles.

NovoTwist® comes in 5 mm (32G Tip) and 8 mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.

Indications and Usage
What is Levemir® (insulin detemir [rDNA origin] injection)?

Important Safety Information

Who should not use Levemir®?

What should I tell my health care provider before taking Levemir®?

How should I take Levemir®?

What should I consider while using Levemir®?

What are the possible side effects of Levemir®?

Please visit levemir.com for Prescribing Information.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit www.novonordisk-us.com.

About Diabetes
In the United States, 25.8 million people have diabetesi, a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life.

Further information

Media:
Katrine Sperling(+45) 4442 6718)krsp@novonordisk.com
In North America:
Sarah Spielvogel(+1) 609 786 4278sspv@novonordisk.com
Investors
Klaus Bülow Davidsen(+45) 4442 3176klda@novonordisk.com
Frank Daniel Mersebach(+45) 4442 0604fdni@novonordisk.com
Lars Borup Jacobsen(+45) 3075 3479lbpj@novonordisk.com
In North America:
Jannick Lindegaard(+1) 609 786 4575jlis@novonordisk.com

i 2011 National Diabetes Fact Sheet. Centers for Disease Control Website. http://www.cdc.gov/diabetes/pubs/factsheet11.htm

###

FlexPen®, FlexTouch®, Levemir®, NovoLog®, NovoFine®, and NovoTwist® are registered trademarks of Novo Nordisk A/S.

©2013 Novo Nordisk All rights reserved. 0813-00017799-1 November 2013

Photo Gallery

NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch®
NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch®
NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch®
NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch®
Levemir® (insulin detemir [DNA origin] injection) FlexTouch®
Levemir® (insulin detemir [DNA origin] injection) FlexTouch®
Levemir® (insulin detemir [DNA origin] injection) FlexTouch®
Levemir® (insulin detemir [DNA origin] injection) FlexTouch®

Related Links

www.novonordisk-us.com
www.novolog.com
www.levemir.com